Recent studies have shown that blocking PD-1/PDL-1 axis via anti-PD-1 and anti-PDL-1 antibodies triggers autophagy in tumor cells and the addition of autophagy inhibitors can serve as an attractive combination immunotherapy approach [25]. Here, PDCD1 is linked to neoplasm.